Canonical owner for coronary imaging and aortic-valve baseline planning in very high Lp(a). Old 2024 RPPH papers now document mild right common-femoral plaque/PAD, but coronary and valve burden remain unstaged. CAC is the low-friction coronary plaque anchor, but CAC=0 does not exclude low-density non-calcified plaque or valve disease. CCTA answers plaque anatomy/composition when symptoms, positive CAC, known peripheral plaque, or cardiology need justify it; transthoracic echo separately answers Lp(a)-linked aortic sclerosis/stenosis, LV response, and valve surveillance. RPPH has a real public coronary-CT route signal, but CAC-vs-CCTA deliverables and plaque-report fields must be confirmed before booking.
cardiovascular · imaging · cac · ccta · ldncp · lp(a) · echo · aortic-stenosis · ct-screening · phnom-penh
This is the single current owner for CAC/CCTA/AI-QCT, CT screening boundaries, echo, and aortic-valve surveillance.
Very high Lp(a) creates two different imaging questions:
Old RPPH papers found in June 2026 add one important baseline: a 2024-01-22 right-leg arterial Doppler already showed mild peripheral atherosclerosis/PAD — mixed plaque in the right common femoral artery with 24-31% stenosis, plus thin calcified/soft plaque in SFA/popliteal artery without significant stenosis. That is not coronary imaging and does not answer the aortic-valve question, but it means the cardiovascular workup is no longer starting from “no documented plaque anywhere.” Archive ID: rpph-2024-01-22-cardiology-orthopedic-papers.
CAC is the simplest coronary anchor if asymptomatic and logistics matter. But CAC measures calcified plaque only. In high Lp(a), the blind spot is low-density/non-calcified plaque detectable by CCTA/quantitative plaque analysis. Echo is not optional “extra CT detail”; it answers a separate Lp(a)-valve question that CAC/CCTA do not answer.
The early-April 2025 severe epigastric/upper-abdominal/chest-ish pain with sweating/dizziness/left-arm or hand symptoms is a symptom override: if that pattern recurs, do same-day ECG + high-sensitivity troponin / possible-ACS rule-out first. That is not screening.
| Situation / result | Meaning | Next step |
|---|---|---|
| Mild peripheral plaque already documented (2024 RPPH Doppler) | Extracoronary disease exists; coronary/valve burden still unknown | Use this as a lower threshold for cardiology discussion and for choosing CAC/CCTA + echo rather than postponing imaging indefinitely. |
| No echo/CAC/CCTA yet | Coronary and valve burden unknown | Baseline echo + decide CAC vs CCTA route. |
| Asymptomatic and cost/logistics matter | Need a low-friction coronary plaque anchor despite known mild peripheral plaque | CAC + baseline echo is the default efficient pair; CCTA is reasonable if cardiology wants anatomy/plaque composition directly. |
| CAC = 0 | Low near-term calcified plaque burden; not a full all-clear | Continue ApoB/LDL, BP, smoking abstinence, symptom vigilance, echo/valve logic. CCTA only if symptoms/specialist concern/direct plaque-composition question justifies it. |
| CAC 1-99 | Early calcified plaque | Cardiology discussion; LDL/ApoB target and CCTA need depend on symptoms and whether plaque composition would change treatment. |
| CAC 100-399 | Meaningful plaque burden | Cardiology review; consider CCTA or functional testing according to symptoms/plan. |
| CAC >=400 | High calcified plaque burden | Specialist-directed coronary workup; screening logic is over. |
| Symptoms recur with autonomic/arm features | Possible ACS/ischemia | Same-day ECG + high-sensitivity troponin first; CCTA/cardiology after acute rule-out if appropriate. |
| High-quality CCTA / AI-QCT available and affordable | Directly answers plaque anatomy/composition | Reasonable to skip CAC-first after shared decision, but verify report contents before paying. |
| Normal echo / no LVH | Good valve/LV baseline | Repeat only by murmur/symptom/BP trigger or clinician-selected multi-year interval; avoid anxiety scanning. |
| Aortic sclerosis / calcification without stenosis | Lp(a)-consistent valve signal, not hemodynamically severe | Cardiology-selected interval, commonly a few years; sooner if symptoms/murmur/pulse pressure/report concern. |
| Mild aortic stenosis | Early hemodynamic disease | Often 2-3 year follow-up in younger mild AS without significant calcification; with high Lp(a)/calcification, use cardiologist interval. |
| Moderate aortic stenosis | Active valve surveillance | At least annual reassessment per ESC-style logic. |
| Severe aortic stenosis | Specialist/valve-clinic domain | At least every 6 months and intervention-timing pathway. |
| Wide pulse pressure or sustained high BP | Vascular-aging/afterload signal | Finish 7-day home BP and consider ABPM if conflict/morning/nocturnal concern. |
| Task | Practical rule |
|---|---|
| Baseline echo | Ask for aortic valve morphology/calcification, Vmax, mean gradient, AVA if measurable, LV size/function, LVH, atrial size, aortic root/ascending aorta, and any valve regurgitation. |
| CAC/CCTA confirmation | Before paying, ask: “Is this non-contrast CAC, contrast CCTA, or both? Is ECG gating used? Do you report Agatston score, stenosis, non-calcified plaque, low-attenuation plaque, positive remodeling, spotty calcification, napkin-ring sign, valve/aorta observations, radiation dose, and standalone/package price?” |
| RPPH local route | RPPH publicly lists 128-slice CT, a CT coronary-screening page, and 2026 Heart Package Platinum with CTA Coronary. Treat as real local route signal, but phone-confirm deliverables/report fields. |
| Bangkok fallback | Use if Phnom Penh cannot clearly answer CAC/CCTA/report contents, or if quantitative/AI plaque analysis is the specific goal. Standard expert CCTA is still valuable even without AI-QCT. |
| BP link | Do not chase arterial-stiffness gadgets before the 7-day BP dataset exists. Pulse pressure comes “free” from the BP log and matters most if echo shows LVH/valve/aorta findings. |
| LDCT lung screening | Only if careful smoking reconstruction reaches guideline threshold (USPSTF-style age 50-80, >=20 pack-years, current smoker or quit <15 years) or clinician has symptom-based reason. |
| Abdomen/pelvis CT | Not for routine bloating or isolated occult stool blood. Use for acute persistent focal/systemic pain, fever, obstruction, abscess/perforation concern, weight loss, abnormal exam/labs, or clinician-directed structural workup. |
| Avoid | Reason |
|---|---|
| Do not treat CAC=0 as an Lp(a) all-clear | It misses non-calcified plaque and does not answer valve, BP, LV, or future smoking-risk questions. |
| Do not treat echo as replaceable by CAC/CCTA | Echo answers valve hemodynamics and LV response; CT answers coronary plaque. |
| Do not ask CCTA to diagnose true thin-cap fibroatheroma | TCFA is histology/intravascular imaging; CCTA reports related high-risk features. |
| Do not buy “AI plaque” marketing without report fields | Confirm actual non-calcified/low-attenuation/total plaque volume and stenosis fields before paying a premium. |
| Do not do full-body CT screening | Incidentaloma/radiation/follow-up burden without proven net benefit. |
| Do not use abdominal CT for ordinary bloating | Bloating/SIBO/SUDD symptoms belong to the symptom owner unless acute/structural triggers appear. |
| Do not turn normal echo into frequent anxiety surveillance | If valve is normal, repeat by symptom/murmur/BP/clinician interval, not habit. |
Preserved evidence anchors include Lp(a)/CCTA non-calcified or high-risk plaque evidence (PMID: 36503252; PMID: 38692827; PMID: 42054506; PMID: 41908166), statin plaque-composition effects (PMID: 29909109; PMID: 32160786), AI-QCT/quantitative CCTA evidence (PMID: 38752951; PMCID: PMC11683154), CAC/Lp(a) risk refinement and CAC=0 limitations (PMID: 38300625; PMID: 39012945), ACC/AHA CAC guidance (PMID: 30423393; PMID: 30879355), ESC chronic coronary syndrome/CCTA guidance (PMID: 39210710), Lp(a)-aortic-valve evidence and progression (PMID: 23388002; PMID: 24161338; PMID: 39018080; PMID: 26361154; PMID: 31047003), ESC/EACTS valve surveillance guidance (PMID: 34453165), BP variability/arterial-stiffness context (PMID: 27906836; PMCID: PMC11901005), and ACR/FDA/USPSTF cautions against broad CT screening.